Novartis Ligelizumab (QGE031) Receives FDA Breakthrough Therapy Designation for Patients with Chronic Idiopathic Urticaria (CIU)

East Hanover, January 14, 2021 — Novartis today announced that the US Food and Drug Administration (FDA) has granted ligelizumab (QGE031) Breakthrough Therapy designation for the treatment of chronic idiopathic urticaria (CIU), also known...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials